SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190873

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190873

Structural Heart Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 192 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Structural Heart Devices Market reached USD 19 billion in 2025 and is projected to grow at 8.4% CAGR from 2026 to 2035. The market is expected to cross USD 43.02 billion valuation by 2035.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$19 Billion
Forecast Value$43.02 Billion
CAGR8.4%

CVDs caused 19.2 million deaths globally in 2023, with ischemic heart disease affecting 240 million people. Expanding prevalence of valve disease and structural cardiac abnormalities in an aging population enlarges the addressable patient pool for transcatheter and surgical structural heart procedures. Sustained burden development path supports above-average procedure volume growth through 2035, especially in regions with expanding elderly cohorts and improving diagnosis rates. Over 106,000 TAVR procedures were performed across U.S. centers in 2024. High and rising procedural volumes confirm robust structural heart program activity, supporting per-procedure device revenue and a growing base of existing installations with upgrade and revision potential. Continued procedural volume growth, broadening indications into moderate and low-risk patients, and expanding mitral and tricuspid platforms support forecast-period revenue growth. CT-based three-dimensional anatomical assessment, AI-allowed valve sizing simulation, and low-profile advanced delivery systems enabling complex structural anatomy access. Iterative platform advancement extends treatment eligibility to younger and anatomically challenging patients, adding new procedure categories and replacement demand on top of primary procedure growth. Successive-generation device launches and installed equipment revision cycles sustain dual revenue streams throughout the forecast period. Cardiovascular disease continues as the leading cause of death globally, accounting for 19.8 million deaths in 2022, or approximately 32% of all deaths worldwide. For structural heart suppliers, patient numbers alone do not determine procedures. Diagnosis, referral, and multidisciplinary assessment influence whether valve disease, septal defects, or atrial appendage risks receive intervention. Care networks that recognize suitable patients early and arrange specialist assessment can convert clinical need into treatment. Experience with TAVR provides a practical foundation for extending transcatheter procedures. As heart teams gain procedural confidence, hospitals can extend well-developed imaging, anesthesia, catheterization, and follow-up infrastructure into mitral, tricuspid, and closure therapies. Product innovation strengthens that transition by improving navigability, sizing precision, sealing performance, and access in challenging anatomy. The resulting opportunity is both procedural and replacement-driven: newer platforms can treat additional patients while creating revision demand within an expanding base of existing installations.

Based on product, the Transcatheter heart valves segment generated USD 8.17 billion in 2025. The well-developed role of transcatheter aortic valve replacement and the gradual broadening of transcatheter treatment across mitral, tricuspid, and pulmonary valve disease helps explain their commercial standing. Device selection progressively turns on anatomy-specific sizing, delivery profile, repositionability, durability expectations, and compatibility with valve-in-valve treatment, making platform breadth a central competitive consideration.

Within procedure, the TAVR segment generated USD 8.93 billion in 2025. The procedure continues as the commercial anchor of the market as it has well-developed referral patterns, standardized heart-team workflows, and broad clinical familiarity across risk categories. Its future mix will be influenced by treatment of younger patients, valve-in-valve cases, lifetime management considerations, and the ability of producers to differentiate on hemodynamics, access, and coronary reaccess.

The North America structural heart devices market generated USD 9.12 billion in 2025. The region gains from well-developed structural heart referral networks, advanced imaging capacity, and broad clinical experience with transcatheter valve and closure procedures. Its relative global weight is likely to moderate as emerging regions scale more rapidly, but its base of existing installations, reimbursement infrastructure, and early adoption of successive device generations preserve its role as the well-developed commercial market.

Edwards Lifesciences held over 31.1% of the market in 2025.

Some of the major players in this market are Medtronic, Abbott, Boston Scientific, AtriCure. This structural heart devices market is concentrated, with key players including Edwards Lifesciences, Medtronic plc, Abbott, Boston Scientific Corporation, LivaNova PLC, AtriCure, Artivion (formerly CryoLife), BIOMERICS, BRAILE Biomedica, JenaValve Technology, Lepu Medical Technology, and NuMED Inc. Market leadership develops in response to clinical evidence, regulatory expertise, physician training capabilities, specialist commercial infrastructure, and the ability to support complex structural heart procedures across valve replacement, valve repair, closure, and appendage management applications.

Product Code: 3231

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Product trends
    • 2.2.2 Procedure trends
    • 2.2.3 End use trends
    • 2.2.4 Regional trends
  • 2.3 TAM analysis, 2027 - 2035
  • 2.4 CXO perspectives: strategic imperatives

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Profit margin
    • 3.1.3 Cost structure
    • 3.1.4 Value addition at each stage
    • 3.1.5 Factors affecting the value chain
    • 3.1.6 Disruptions
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing burden of cardiovascular diseases
      • 3.2.1.2 Technological advancements in structural heart interventions
      • 3.2.1.3 Favorable reimbursement scenario
      • 3.2.1.4 Rising preference for minimally invasive procedures
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory policies
      • 3.2.2.2 Potential complications and adverse events
    • 3.2.3 Market opportunities
  • 3.3 Growth potential analysis
  • 3.4 Pricing analysis (Driven by Primary Research)
    • 3.4.1 Historical price trend analysis
    • 3.4.2 Pricing strategy by player type (Premium / Value / Cost-plus)
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia-Pacific
    • 3.5.4 Latin America
    • 3.5.5 Middle East and Africa
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis
  • 3.8 Trade data analysis (Based on Paid Database)
    • 3.8.1 Import/Export volume & value trends
    • 3.8.2 Key trade corridors & tariff impact
  • 3.9 Impact of AI & Generative AI on the market (Driven by Primary Research)
    • 3.9.1 AI-driven disruption of existing business models
    • 3.9.2 GenAI use cases & adoption roadmap by segment
    • 3.9.3 Risks, limitations & regulatory considerations
  • 3.10 Patent / IP landscape
  • 3.11 Medical infrastructure landscape
  • 3.12 Epidemiology / Disease burden

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia-Pacific
      • 4.2.1.4 Latin America
      • 4.2.1.5 Middle East and Africa
    • 4.2.2 Market concentration analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Key developments
    • 4.5.1 Mergers & acquisitions
    • 4.5.2 Partnerships & collaborations
    • 4.5.3 New product launches
    • 4.5.4 Expansion plans and funding
  • 4.6 Company tier benchmarking
    • 4.6.1 Tier classification criteria & qualifying thresholds
    • 4.6.2 Tier positioning matrix by revenue, geography & innovation

Chapter 5. Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Heart valve devices
    • 5.2.1 Surgical heart valves
    • 5.2.2 Transcatheter heart valves
  • 5.3 Annuloplasty rings
  • 5.4 Occluders and delivery systems
  • 5.5 Other products

Chapter 6. Market Estimates and Forecast, By Procedure, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Replacement procedures
    • 6.2.1 Surgical aortic valve replacement (SAVR)
    • 6.2.2 Transcatheter aortic valve replacement (TAVR)
    • 6.2.3 Transcatheter mitral valve replacement (TMVR)
    • 6.2.4 Other replacement procedures
  • 6.3 Repair procedures
    • 6.3.1 Left atrial appendage closure (LAAC)
    • 6.3.2 Transcatheter mitral valve repair (TMVr)
    • 6.3.3 Transcatheter tricuspid valve repair (TTVr)
    • 6.3.4 Valvuloplasty
    • 6.3.5 Other repair procedures

Chapter 7. Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Cardiac catheterization labs
  • 7.5 Other end use

Chapter 8. Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9. Company Profiles

  • 9.1 Global Players
    • 9.1.1 Abbott
    • 9.1.2 Boston Scientific
    • 9.1.3 Edwards Lifesciences
    • 9.1.4 Medtronic
    • 9.1.5 LivaNova
  • 9.2 Regional Players
    • 9.2.1 AtriCure
    • 9.2.2 CryoLife
    • 9.2.3 BIOMERICS
  • 9.3 Emerging Players
    • 9.3.1 BRAILE Biomedica
    • 9.3.2 JENAVALVE Technology
    • 9.3.3 LEPU MEDICAL Technology
    • 9.3.4 NuMED
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!